By Lina carolina 
In the intricate landscape of the human immune system and its battle against cancer, a long-standing paradox has perplexed researchers, particularly concerning colorectal cancer. For years, the prevailing understanding in oncology has been that a high presence of regulatory T (Treg) cells within a tumor environment is a grim indicator, typically associated with poorer patient outcomes. These specialized immune cells, crucial for maintaining immune homeostasis and preventing autoimmune reactions, often act as potent suppressors of anti-cancer immune responses. By dampening the activity of other immune cells, Tregs can inadvertently shield tumors from destruction, allowing them to proliferate and metastasize. However, colorectal cancer, especially its most common form, has consistently defied this rule, presenting a confounding scenario where abundant Treg cells are frequently linked to prolonged patient survival. This anomaly has left the scientific community searching for a clear explanation, a quest that a groundbreaking study from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) now appears to have fulfilled, potentially revolutionizing immunotherapy strategies for a significant patient population.
Decades of Research Culminate in a Monumental Discovery
The pivotal findings, published in the esteemed scientific journal Immunity, propose a nuanced understanding of Treg cell function in colorectal cancer, moving beyond a simple count to a sophisticated appreciation of cell subtypes. The research posits that not all Treg cells are created equal, and their impact on tumor progression is dictated by their specific molecular signature and functional role. This revelation is the culmination of over two decades of dedicated research by Dr. Alexander Rudensky, a world-renowned expert in Treg cell biology and Chair of the Immunology Program at MSK. Dr. Rudensky’s pioneering work has been instrumental in defining the fundamental role of Tregs in maintaining immune tolerance – the critical ability of the immune system to differentiate between self and non-self, harmless and harmful entities, thereby preventing unwarranted attacks on the body’s own tissues, beneficial microbes, and dietary components. His lab has systematically elucidated the origins, mechanisms of action, and influence of Tregs on cancer development, laying the essential groundwork for this latest breakthrough.
The Unique Case of Colorectal Cancer
Colorectal cancer represents a significant global health challenge, ranking as the second leading cause of cancer-related deaths when both men and women are considered, according to the American Cancer Society. The study strategically focused on the most prevalent subtype, known as microsatellite stable (MSS) colorectal cancer with proficient mismatch repair (MMRp). This form accounts for approximately 80-85% of all colorectal cancers and is characterized by relative DNA stability. A critical aspect of MSS/MMRp colorectal cancer is its notoriously poor response to current checkpoint inhibitor immunotherapies, a stark contrast to the highly effective treatment observed in cancers with high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd). These MSI-H/MMRd tumors, often treated successfully with immunotherapy alone, can allow patients to bypass more aggressive treatments like surgery, chemotherapy, and radiation. The differing responses to immunotherapy underscored the need to understand the unique immune microenvironment of MSS/MMRp tumors, and the role of Tregs within them.
Unmasking the Two Faces of Treg Cells in Colorectal Cancer
To dissect the atypical immune behavior in MSS/MMRp colorectal cancer, the MSK research team employed a sophisticated mouse model engineered to accurately replicate the genetic makeup, clinical progression, and immune milieu of human colorectal tumors. Through meticulous investigation, they identified two distinct populations of tumor-associated Treg cells, each exhibiting diametrically opposed effects on tumor growth.
The first group, characterized by the production of a signaling molecule known as interleukin-10 (IL-10), emerged as a benevolent force. These IL-10-positive Tregs were found to actively restrain tumor progression. Their mechanism of action involves suppressing the activity of another immune cell type, Th17 cells, which produce interleukin-17 (IL-17). IL-17, in this context, acts as a growth promoter for colorectal tumors. The protective IL-10-positive Tregs were predominantly located in the healthy tissue surrounding the tumor, suggesting a localized protective role. Experiments involving the selective elimination of these beneficial cells revealed a concerning outcome: tumors grew at an accelerated rate, underscoring their crucial anti-tumor function.
Conversely, the second group, designated as IL-10-negative Treg cells, proved to be detrimental to the anti-cancer immune response. These cells exert their harmful influence by suppressing potent immune defenders, most notably CD8+ T cells, which are the primary architects of tumor cell destruction. This suppressive subtype was found to be concentrated within the tumor itself, acting as a direct barrier to immune-mediated attack. When these IL-10-negative Tregs were experimentally removed, a dramatic and encouraging result was observed: tumors significantly shrank, demonstrating their direct contribution to tumor growth and immune evasion.
Patient Data Validates In Vivo Findings
The scientific rigor of the study was further bolstered by the validation of these findings using human tumor samples obtained from colorectal cancer patients. The analysis of these samples corroborated the existence of two distinct Treg populations – IL-10-positive and IL-10-negative. Crucially, a retrospective analysis of clinical outcomes for over 100 colorectal cancer patients provided compelling evidence of the clinical relevance of these Treg subtypes. Patients whose tumors harbored higher levels of the beneficial IL-10-positive Tregs exhibited significantly longer survival rates. Conversely, those with a greater abundance of the detrimental IL-10-negative Tregs experienced poorer prognoses.
"This research highlights the profound importance of these positive cells," stated Dr. Xiao Huang, a postdoctoral researcher in the Rudensky Lab and a lead author on the study. "It underscores the urgent need to develop therapeutic strategies that can precisely target and eliminate the harmful Tregs while simultaneously preserving the beneficial ones."
A Novel Therapeutic Avenue: Targeting CCR8 for Selective Depletion
The identification of these distinct Treg subtypes opens up a promising new frontier for therapeutic intervention, particularly for the vast majority of colorectal cancer patients who do not benefit from current immunotherapies. The researchers pinpointed a key molecular marker associated with the detrimental IL-10-negative Treg cells: high expression of a protein known as CCR8. This protein is instrumental in the migration and function of these immunosuppressive cells, and their prevalence within the tumor microenvironment.
This discovery builds upon prior foundational research from Dr. Rudensky’s lab, notably a study led by breast cancer surgeon Dr. George Plitas. That earlier work demonstrated that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and a wide spectrum of other human malignancies. The implications of this shared characteristic are profound: therapies designed to target CCR8 could potentially be leveraged to selectively eliminate harmful Treg cells across various cancer types, thereby unleashing the body’s own immune system to mount a more effective attack against tumors, all while leaving the beneficial Treg populations intact.
"The concept of employing CCR8-depleting antibodies, an approach pioneered here at MSK, is now the central focus of global efforts to translate regulatory T cell-based immunotherapy into clinical practice," Dr. Rudensky elaborated. This innovative strategy is currently under investigation in multiple clinical trials at MSK and other leading cancer centers, both as a standalone treatment and in combination with existing immunotherapies. The present study provides robust scientific validation for the application of this CCR8-targeting strategy in colorectal cancer and potentially extends its promise to other cancer types.
Echoes in Other Cancers: A Conserved Immune Mechanism
The researchers extended their inquiry beyond colorectal cancer, examining a comprehensive dataset of T cells from 16 different cancer types. Their aim was to ascertain whether the observed immune patterns in colorectal cancer were unique or if similar Treg dichotomies existed elsewhere. The results revealed striking parallels in several cancers affecting the skin and the mucosal linings of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in their constant defense and repair, as they are continuously exposed to microbes and environmental stressors," explained Dr. Sneha Mitra, a postdoctoral researcher in the lab of computational biologist Dr. Christina Leslie and a co-senior author. Dr. Mitra, who co-mentored by Dr. Leslie and Dr. Rudensky, led the extensive data analysis. This shared characteristic suggests that therapies developed to eliminate IL-10-negative Treg cells in colorectal cancer might prove equally effective against these other cancers arising in barrier tissues, hinting at a broader therapeutic applicability.
Metastatic Disease: A Different Immune Equation
The study also delved into the complex immune landscape of metastatic colorectal cancer, specifically tumors that have spread to the liver. In this advanced stage of the disease, a distinct immune profile emerged. Here, IL-10-negative Treg cells significantly outnumbered their beneficial IL-10-positive counterparts. In a departure from findings in primary tumors, the experimental elimination of all Treg cells in the context of metastatic disease led to a notable reduction in tumor size. This observation underscores the critical need for treatment strategies that are not only tailored to the specific tissue of origin but also account for the stage of disease progression, highlighting the dynamic and context-dependent nature of the immune response in cancer.
The Research Team and Funding
This seminal work was led by first authors Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now affiliated with the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, the study’s other senior author.
The research was supported by significant funding from various esteemed institutions, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-José Kravis Fellowship in Quantitative Biology. The Integrated Genomics Operation and the Single Cell Research Initiative at MSK played crucial roles in facilitating this research.
Several individuals are acknowledged for their contributions, including Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh.
Dr. Rudensky’s significant contributions to the field are further recognized by his role as a Howard Hughes Medical Institute Investigator. He also holds equity in and serves on scientific advisory boards for several biotechnology and pharmaceutical companies, including Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He also acts as a scientific advisory board member for Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor for the Journal of Experimental Medicine and an editorial advisor to Immunity. Notably, Dr. Rudensky and Dr. Plitas are inventors on patents and patent applications held by MSK that relate to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies targeting CCR8, further solidifying the translational potential of this research.
